Ability to embed active components like sensors and holographic films during the printing process; protected by Printoptical® Technology patents.
Differentiation
Value Proposition
Enables 'One-Step-Cad-to-Optic' printing of clear prescription lenses, reducing lead times and allowing integration of electronics, waveguides, and LCDs directly into the lens.
How They Differentiate
Pioneer and only company currently capable of 3D printing ophthalmic-grade prescription lenses at volume without post-print polishing.
Production grew from 5,000 lenses/year in 2018 to 50,000+ total by 2022; estimated revenue $6-6.7M.
Major Milestones
2009: World's first 3D printed functional glasses; 2017: First US lab installations; 2019: Reached 5,000 lenses/year production rate; 2022: Reached 50,000 lenses total production milestone; 2022: Acquired by Meta
Luxexcel occupies a unique position in additive manufacturing as the only company capable of volume-producing ophthalmic-grade prescription lenses directly from a printer without post-print polishing. Its proprietary Printoptical Technology uses a resin jetting process that achieves optical clarity in a single step, eliminating the grinding and polishing required by conventional lens manufacturing. This allows Luxexcel to serve both traditional eyewear labs and the emerging smart eyewear market.
The company's core offering includes the VisionEngine printer, VisionMaster software, and VisionClear resin, which together enable a one-step cad-to-optic workflow. Beyond clear lenses, the technology can embed active components such as sensors, waveguides, and LCDs during printing, making it relevant for augmented reality and heads-up display applications. Luxexcel's process is based on vat photopolymerization (VPP-SLA) and is protected by its Printoptical Technology patents.
Luxexcel targets ophthalmic labs and smart eyewear manufacturers. Its most notable customer is Meta, which acquired Luxexcel in 2022 and uses the technology for Project Aria smart glasses. The company also partners with independent ophthalmic labs. Production grew from 5,000 lenses per year in 2018 to over 50,000 total by 2022, with estimated revenue of $6-7 million. Investors include Innovation Industries, SET Ventures, and PMV.
The company's strategic moat lies in its first-mover position and proprietary process for printing optical-quality lenses at volume. However, its acquisition by Meta creates an open question about long-term independence and whether the technology will remain available to third-party labs. Competitors such as LuxCreo, Nanofabrica, and Carbon have not matched Luxexcel's ability to print prescription lenses without post-processing, but they could develop competing approaches as the smart eyewear market expands.
Competitive Intelligence
Competitors, SWOT analysis, and investment insights